Bridgeway Capital Management’s Trevi Therapeutics TRVI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $246K | Sell |
44,981
-35,000
| -44% | -$191K | 0.01% | 916 |
|
|
2025
Q1 | $503K | Sell |
79,981
-97,500
| -55% | -$613K | 0.01% | 744 |
|
|
2024
Q4 | $731K | Sell |
177,481
-8,000
| -4% | -$33K | 0.02% | 735 |
|
|
2024
Q3 | $620K | Hold |
185,481
| – | – | 0.01% | 810 |
|
|
2024
Q2 | $553K | Buy |
185,481
+89,000
| +92% | +$265K | 0.01% | 836 |
|
|
2024
Q1 | $333K | Sell |
96,481
-115,000
| -54% | -$397K | 0.01% | 1018 |
|
|
2023
Q4 | $283K | Buy |
211,481
+25,000
| +13% | +$33.5K | 0.01% | 1070 |
|
|
2023
Q3 | $407K | Hold |
186,481
| – | – | 0.01% | 937 |
|
|
2023
Q2 | $446K | Sell |
186,481
-1,919
| -1% | -$4.59K | 0.01% | 933 |
|
|
2023
Q1 | $349K | Sell |
188,400
-20,000
| -10% | -$37K | 0.01% | 969 |
|
|
2022
Q4 | $402K | Buy |
208,400
+49,100
| +31% | +$94.8K | 0.01% | 932 |
|
|
2022
Q3 | $245K | Buy |
159,300
+56,700
| +55% | +$87.2K | 0.01% | 1093 |
|
|
2022
Q2 | $288K | Buy |
102,600
+27,600
| +37% | +$77.5K | 0.01% | 1003 |
|
|
2022
Q1 | $165K | Hold |
75,000
| – | – | ﹤0.01% | 1198 |
|
|
2021
Q4 | $59K | Buy |
75,000
+40,400
| +117% | +$31.8K | ﹤0.01% | 1239 |
|
|
2021
Q3 | $47K | Hold |
34,600
| – | – | ﹤0.01% | 1274 |
|
|
2021
Q2 | $78K | Sell |
34,600
-75,000
| -68% | -$169K | ﹤0.01% | 1315 |
|
|
2021
Q1 | $299K | Buy |
109,600
+9,600
| +10% | +$26.2K | 0.01% | 1221 |
|
|
2020
Q4 | $242K | Hold |
100,000
| – | – | 0.01% | 1172 |
|
|
2020
Q3 | $403K | Hold |
100,000
| – | – | 0.01% | 977 |
|
|
2020
Q2 | $658K | Buy |
100,000
+25,000
| +33% | +$165K | 0.01% | 778 |
|
|
2020
Q1 | $247K | Hold |
75,000
| – | – | 0.01% | 994 |
|
|
2019
Q4 | $281K | Buy |
+75,000
| New | +$281K | ﹤0.01% | 1137 |
|